Nanomedicine and graphene-based materials: advanced technologies for potential treatments of diseases in the developing nervous system.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
01
04
2021
accepted:
26
07
2021
revised:
20
07
2021
pubmed:
5
9
2021
medline:
30
8
2022
entrez:
4
9
2021
Statut:
ppublish
Résumé
The interest in graphene-based nanomaterials (GBNs) application in nanomedicine, in particular in neurology, steadily increased in the last decades. GBNs peculiar physical-chemical properties allow the design of innovative therapeutic tools able to manipulate biological structures with subcellular resolution. In this review, we report GBNs applications to the central nervous system (CNS) when these nanomaterials are engineered as potential therapeutics to treat brain pathologies, with a focus on those of the pediatric age. We revise the state-of-the art studies addressing the impact of GBNs in the CNS, showing that the design of GBNs with different dimensions and chemical compositions or the use of specific administration routes and doses can limit unwanted side effects, exploiting GBNs efficacy in therapeutic approaches. These features favor the development of GBNs-based multifunctional devices that may find applications in the field of precision medicine for the treatment of disorders in the developing CNS. In this framework, we address the suitability of GBNs to become successful therapeutic tools, such as drug nano-delivery vectors when being chemically decorated with pharmaceutical agents and/or other molecules to obtain a high specific targeting of the diseased area and to achieve a controlled release of active molecules. IMPACT: The translational potential of graphene-based nanomaterials (GBNs) can be used for the design of novel therapeutic approaches to treat pathologies affecting the brain with a focus on the pediatric age. GBNs can be chemically decorated with pharmaceutical agents and molecules to obtain a highly specific targeting of the diseased site and a controlled drug release. The type of GBNs, the selected functionalization, the dose, and the way of administration are factors that should be considered to potentiate the therapeutic efficacy of GBNs, limiting possible side effects. GBNs-based multifunctional devices might find applications in the precision medicine and theranostics fields.
Identifiants
pubmed: 34480086
doi: 10.1038/s41390-021-01681-6
pii: 10.1038/s41390-021-01681-6
pmc: PMC9411050
doi:
Substances chimiques
Pharmaceutical Preparations
0
Graphite
7782-42-5
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-79Informations de copyright
© 2021. The Author(s).
Références
Geim, A. K. Graphene: status and prospects. Science 324, 1530–1534 (2009).
pubmed: 19541989
doi: 10.1126/science.1158877
Kostarelos, K. & Novoselov, K. S. Exploring the interface of graphene and biology. Mater. Sci. 21, 261–263 (2020).
Sanchez, V. C., Jachak, A., Hurt, R. H. & Kane, A. B. Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem. Res. Toxicol. 25, 15–34 (2012).
pubmed: 21954945
doi: 10.1021/tx200339h
Xia, Y. Nanomaterials at work in biomedical research. Nat. Mater. 7, 758–760 (2008).
pubmed: 18813296
doi: 10.1038/nmat2277
Zhang, B. et al. Synaptic vesicle size and number are regulated by a clathrin adaptor protein required for endocytosis. Neuron 21, 1465–1475 (1998).
pubmed: 9883738
doi: 10.1016/S0896-6273(00)80664-9
Smith, K. R. et al. Psychiatric risk factor ANK3/Ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses. Neuron 84, 399–415 (2014).
pubmed: 25374361
pmcid: 4223651
doi: 10.1016/j.neuron.2014.10.010
Pchitskaya, E. & Bezprozvanny, I. Dendritic spines shape analysis—classification or clusterization? Perspective. Front. Synaptic Neurosci. 12, 31 (2020).
pubmed: 33117142
pmcid: 7561369
doi: 10.3389/fnsyn.2020.00031
Silva, G. A. Neuroscience nanotechnology: progress, opportunities and challenges. Nat. Rev. Neurosci. 7, 65–74 (2006).
pubmed: 16371951
doi: 10.1038/nrn1827
Bramini, M. et al. Interfacing graphene-based materials with neural cells. Front. Syst. Neurosci. 12, 1–22 (2018).
doi: 10.3389/fnsys.2018.00012
Kitko, K. E. & Zhang, Q. Graphene-based nanomaterials: From production to integration with modern tools in neuroscience. Front. Syst. Neurosci. 13, 1–17 (2019).
doi: 10.3389/fnsys.2019.00026
Yang, S., Wallach, M., Krishna, A., Kurmasheva, R. & Sridhar, S. Recent developments in nanomedicine for pediatric cancer. J. Clin. Med. 10, 1437 (2021).
pubmed: 33916177
pmcid: 8036287
doi: 10.3390/jcm10071437
Sosnik, A. & Carcaboso, A. M. Nanomedicines in the future of pediatric therapy. Adv. Drug Deliv. Rev. 73, 140–161 (2014).
pubmed: 24819219
doi: 10.1016/j.addr.2014.05.004
Fadeel, B. et al. Safety assessment of graphene-based materials: focus on human health and the environment. ACS Nano 12, 10582–10620 (2018).
pubmed: 30387986
doi: 10.1021/acsnano.8b04758
Rauti, R. et al. Graphene oxide nanosheets reshape synaptic function in cultured brain networks. ACS Nano 10, 4459–4471 (2016).
pubmed: 27030936
doi: 10.1021/acsnano.6b00130
Bramini, M. et al. Graphene oxide nanosheets disrupt lipid composition, Ca2+ homeostasis, and synaptic transmission in primary cortical neurons. ACS Nano 10, 7154–7171 (2016).
pubmed: 27359048
doi: 10.1021/acsnano.6b03438
Secomandi, N., Franceschi Biagioni, A., Kostarelos, K., Cellot, G. & Ballerini, L. Thin graphene oxide nanoflakes modulate glutamatergic synapses in the amygdala cultured circuits: exploiting synaptic approaches to anxiety disorders. Nanomed. Nanotechnol. Biol. Med. 26, 102174 (2020).
doi: 10.1016/j.nano.2020.102174
Cellot, G. et al. Graphene oxide nanosheets modulate spinal glutamatergic transmission and modify locomotor behaviour in an in vivo zebrafish model. Nanoscale Horiz. 5, 1250–1263 (2020).
pubmed: 32558850
doi: 10.1039/C9NH00777F
Wang, H. et al. Pristine graphene dispersion in solvents and its application as a catalyst support: A combined theoretical and experimental study. J. Mater. Chem. A 3, 6282–6285 (2015).
doi: 10.1039/C5TA00359H
Zhang, Y. et al. Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytoma-derived pc12 cells. ACS Nano 4, 3181–3186 (2010).
pubmed: 20481456
doi: 10.1021/nn1007176
Ali-Boucetta, H. et al. Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity. Adv. Healthc. Mater. 2, 433–441 (2013).
pubmed: 23184580
doi: 10.1002/adhm.201200248
Ray, S. & Jana, N. Carbon Nanomaterials for Biological and Medical Applications 1st edn (Elsevier, 2017).
Lv, M. et al. Effect of graphene oxide on undifferentiated and retinoic acid-differentiated SH-SY5Y cells line. Nanoscale 4, 3861–3866 (2012).
pubmed: 22653613
doi: 10.1039/c2nr30407d
Rauti, R. et al. Graphene oxide flakes tune excitatory neurotransmission in vivo by targeting hippocampal synapses. Nano Lett. 19, 2858–2870 (2019).
pubmed: 30983361
doi: 10.1021/acs.nanolett.8b04903
Kang, Y. et al. Oxidation of reduced graphene oxide via cellular redox signaling modulates actin-mediated neurotransmission. ACS Nano 14, 3059–3074 (2020).
pubmed: 32057235
doi: 10.1021/acsnano.9b08078
Chiacchiaretta, M. et al. Graphene oxide upregulates the homeostatic functions of primary astrocytes and modulates astrocyte-to-neuron communication. Nano Lett. 18, 5827–5838 (2018).
pubmed: 30088941
doi: 10.1021/acs.nanolett.8b02487
Bramini, M. et al. An increase in membrane cholesterol by graphene oxide disrupts calcium homeostasis in primary astrocytes. Small 15, 1–14 (2019).
doi: 10.1002/smll.201900147
Brocke, K. S. et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol. Ther. 9, 455–468 (2010).
pubmed: 20061814
doi: 10.4161/cbt.9.6.10898
Naaijen, J. et al. Fronto-striatal glutamate in children with Tourette’s disorder and attention-deficit/hyperactivity disorder. NeuroImage Clin. 13, 16–23 (2017).
pubmed: 27909683
doi: 10.1016/j.nicl.2016.11.013
Macmaster, F. P. Translational neuroimaging research in pediatric obsessive-compulsive disorder. Dialog. Clin. Neurosci. 12, 165–174 (2010).
doi: 10.31887/DCNS.2010.12.2/fmacmaster
Barker-Haliski, M. & White, S. H. Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb. Perspect. Med. 5, 1–15 (2015).
doi: 10.1101/cshperspect.a022863
Franceschi Biagioni, A. et al. Graphene oxide prevents lateral amygdala dysfunctional synaptic plasticity and reverts long lasting anxiety behavior in rats. Biomaterials 271, 120749 (2021).
pubmed: 33714913
doi: 10.1016/j.biomaterials.2021.120749
Defterali, Ç. et al. Thermally reduced graphene is a permissive material for neurons and astrocytes and de novo neurogenesis in the adult olfactory bulb in vivo. Biomaterials 82, 84–93 (2016).
pubmed: 26751821
doi: 10.1016/j.biomaterials.2015.12.010
Portioli, C. et al. Intracerebral injection of graphene oxide nanosheets mitigates microglial activation without inducing acute neurotoxicity: a pilot comparison to other nanomaterials. Small 16, 1–15 (2020).
doi: 10.1002/smll.202004029
Wang, P. P., Frazier, J. & Brem, H. Local drug delivery to the brain. Adv. Drug Deliv. Rev. 54, 987–1013 (2002).
pubmed: 12384318
doi: 10.1016/S0169-409X(02)00054-6
West, S., Nolan, S. J. & Newton, R. Surgery for epilepsy: a systematic review of current evidence. Epileptic Disord. 18, 113–121 (2016).
pubmed: 27193634
doi: 10.1684/epd.2016.0825
Chen, S. et al. Mass spectrometry imaging reveals the sub-organ distribution of carbon nanomaterials. Nat. Nanotechnol. 10, 176–182 (2015).
pubmed: 25652170
doi: 10.1038/nnano.2014.282
Zhang, X. et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon N. Y. 49, 986–995 (2011).
doi: 10.1016/j.carbon.2010.11.005
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R. & Zlokovic, B. V. Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019).
pubmed: 30280653
doi: 10.1152/physrev.00050.2017
Mendonça, M. C. P. et al. Reduced graphene oxide induces transient blood-brain barrier opening: an in vivo study. J. Nanobiotechnol. 13, 1–13 (2015).
doi: 10.1186/s12951-015-0143-z
Su, S. et al. In vitro study of transportation of porphyrin immobilized graphene oxide through blood brain barrier. Mater. Sci. Eng. C 107, 110313 (2020).
doi: 10.1016/j.msec.2019.110313
Newman, L. et al. Nose-to-brain translocation and cerebral biodegradation of thin graphene oxide nanosheets. Cell Rep. Phys. Sci. 1, 100176 (2020).
doi: 10.1016/j.xcrp.2020.100176
Zhang, D. et al. The short- and long-term effects of orally administered high-dose reduced graphene oxide nanosheets on mouse behaviors. Biomaterials 68, 100–113 (2015).
pubmed: 26276695
doi: 10.1016/j.biomaterials.2015.07.060
Sood, K., Kaur, J., Singh, H., Kumar Arya, S. & Khatri, M. Comparative toxicity evaluation of graphene oxide (GO) and zinc oxide (ZnO) nanoparticles on Drosophila melanogaster. Toxicol. Rep. 6, 768–781 (2019).
pubmed: 31428565
pmcid: 6695280
doi: 10.1016/j.toxrep.2019.07.009
Li, P., Xu, T., Wu, S., Lei, L. & He, D. Chronic exposure to graphene-based nanomaterials induces behavioral deficits and neural damage in Caenorhabditis elegans. J. Appl. Toxicol. 37, 1140–1150 (2017).
pubmed: 28418071
doi: 10.1002/jat.3468
Hu, X., Wei, Z. & Mu, L. Graphene oxide nanosheets at trace concentrations elicit neurotoxicity in the offspring of zebrafish. Carbon N. Y. 117, 182–191 (2017).
doi: 10.1016/j.carbon.2017.02.092
Soares, J. C. et al. Developmental neurotoxic effects of graphene oxide exposure in zebrafish larvae (Danio rerio). Colloids Surf. B Biointerfaces 157, 335–346 (2017).
pubmed: 28618356
doi: 10.1016/j.colsurfb.2017.05.078
Manjunatha, B., Seo, E., Park, S. H., Kundapur, R. R. & Lee, S. J. Pristine graphene and graphene oxide induce multi-organ defects in zebrafish (Danio rerio) larvae/juvenile: an in vivo study. Environ. Sci. Pollut. Res. 28, 34664–34675 (2021).
Shang, S., Yang, S. Y., Liu, Z. M. & Yang, X. Oxidative damage in the kidney and brain of mice induced by different nano-materials. Front. Biol. 10, 91–96 (2015).
doi: 10.1007/s11515-015-1345-3
John, A. A. et al. Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery. Int. J. Nanomed. 10, 4267–4277 (2015).
Guo, Z. et al. Elucidating the mechanism of the surface functionalization dependent neurotoxicity of graphene family nanomaterials. Nanoscale 12, 18600–18605 (2020).
pubmed: 32914812
doi: 10.1039/D0NR04179C
Chen, Y., Star, A. & Vidal, S. Sweet carbon nanostructures: carbohydrate conjugates with carbon nanotubes and graphene and their applications. Chem. Soc. Rev. 42, 4532–4542 (2013).
pubmed: 23247183
doi: 10.1039/C2CS35396B
Georgakilas, V. et al. Noncovalent functionalization of graphene and graphene oxide for energy materials, biosensing, catalytic, and biomedical applications. Chem. Rev. 116, 5464–5519 (2016).
pubmed: 27033639
doi: 10.1021/acs.chemrev.5b00620
Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).
pubmed: 31601988
doi: 10.1038/s41568-019-0205-x
Kaatsch, P. Epidemiology of childhood cancer. Cancer Treat. Rev. 36, 277–285 (2010).
pubmed: 20231056
doi: 10.1016/j.ctrv.2010.02.003
Weil, A. G. et al. Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication. J. Neurooncol. 132, 99–107 (2017).
pubmed: 27981412
doi: 10.1007/s11060-016-2341-4
Castellino, S. M., Ullrich, N. J., Whelen, M. J. & Lange, B. J. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J. Natl Cancer Inst. 106, 1–16 (2014).
doi: 10.1093/jnci/dju186
Marusak, H. A. et al. Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes. Neuropsychol. Rev. 28, 123–175 (2018).
pubmed: 29270773
doi: 10.1007/s11065-017-9365-1
Izycka-Swieszewska, E. et al. Malignant gliomas as second neoplasms in pediatric cancer survivors: neuropathological study. Biomed. Res. Int. 2018, 4596812 (2018).
Liu, Z., Robinson, J. T., Sun, X. & Dai, H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130, 10876–10877 (2008).
pubmed: 18661992
pmcid: 2597374
doi: 10.1021/ja803688x
Mendonça, M. C. P. et al. PEGylation of reduced graphene oxide induces toxicity in cells of the blood-brain barrier: an in vitro and in vivo study. Mol. Pharm. 13, 3913–3924 (2016).
pubmed: 27712077
doi: 10.1021/acs.molpharmaceut.6b00696
Lu, Y. J. et al. Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. Int. J. Nanomed. 7, 1737–1747 (2012).
Ye, Y., Mao, X., Xu, J., Kong, J. & Hu, X. Functional graphene oxide nanocarriers for drug delivery. Int. J. Polym. Sci. 2019, 7 (2019).
doi: 10.1155/2019/8453493
Pérez-Herrero, E. & Fernández-Medarde, A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52–79 (2015).
pubmed: 25813885
doi: 10.1016/j.ejpb.2015.03.018
Liu, G. et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. ACS Appl. Mater. Interfaces 5, 6909–6914 (2013).
pubmed: 23883622
doi: 10.1021/am402128s
Xiong, S. et al. Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson’s disease. Biomater. Sci. 9, 1705–1715 (2021).
pubmed: 33427264
doi: 10.1039/D0BM01765E
Swietach, P., Vaughan-Jones, R. D., Harris, A. L. & Hulikova, A. The chemistry, physiology and pathology of pH in cancer. Philos. Trans. R. Soc. B Biol. Sci. 369, 20130099 (2014).
doi: 10.1098/rstb.2013.0099
Kavitha, T., Haider Abdi, S. I. & Park, S. Y. PH-Sensitive nanocargo based on smart polymer functionalized graphene oxide for site-specific drug delivery. Phys. Chem. Chem. Phys. 15, 5176–5185 (2013).
pubmed: 23454895
doi: 10.1039/c3cp00008g
Wang, Y. et al. Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. J. Am. Chem. Soc. 135, 4799–4804 (2013).
pubmed: 23495667
doi: 10.1021/ja312221g
Mancilla, T. R., Iskra, B. & Aune, G. J. Doxorubicin-induced cardiomyopathy in children. Compr. Physiol. 9, 905–931 (2020).
Orecchioni, M., Cabizza, R., Bianco, A. & Delogu, L. G. Graphene as cancer theranostic tool: progress and future challenges. Theranostics 5, 710–723 (2015).
pubmed: 25897336
pmcid: 4402495
doi: 10.7150/thno.11387
Garg, B., Sung, C. H. & Ling, Y. C. Graphene-based nanomaterials as molecular imaging agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7, 737–758 (2015).
pubmed: 25857851
doi: 10.1002/wnan.1342
Chen, F., Ehlerding, E. B. & Cai, W. Theranostic nanoparticles. J. Nucl. Med. 55, 1919–1922 (2014).
pubmed: 25413134
doi: 10.2967/jnumed.114.146019
Yang, H. W. et al. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials 35, 6534–6542 (2014).
pubmed: 24811259
doi: 10.1016/j.biomaterials.2014.04.057
Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635–647 (2005).
pubmed: 15766527
doi: 10.1016/j.cell.2005.01.014
Wang, X. Y. et al. The permeability and transport mechanism of graphene quantum dots (GQDs) across the biological barrier. Nanoscale 7, 2034–2041 (2015).
pubmed: 25553649
doi: 10.1039/C4NR04136D
Tak, K., Sharma, R., Dave, V., Jain, S. & Sharma, S. Clitoria ternatea mediated synthesis of graphene quantum dots for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 11, 3741–3748 (2020).
pubmed: 33119989
doi: 10.1021/acschemneuro.0c00273
Perini, G. et al. Graphene quantum dots’ surface chemistry modulates the sensitivity of glioblastoma cells to chemotherapeutics. Int. J. Mol. Sci. 21, 1–17 (2020).
doi: 10.3390/ijms21176301
Perini, G. et al. Enhanced chemotherapy for glioblastoma quantum dots. Materials 13, 4139 (2020).
pmcid: 7560355
doi: 10.3390/ma13184139
Chowdhury, S. M. et al. Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme. Nanomedicine 11, 109–118 (2015).
pubmed: 25131339
doi: 10.1016/j.nano.2014.08.001
Reddy, S. et al. Reduced graphene oxide-based electrochemically stimulated method for temozolomide delivery. Med. Devices Sens. 1, e10014 (2018).
doi: 10.1002/mds3.10014
Sarecka-Hujar, B. & Kopyta, I. Risk factors for recurrent arterial ischemic stroke in children and young adults. Brain Sci. 10, 1–20 (2020).
doi: 10.3390/brainsci10010024
Wu, Q., Qin, M. & Zhang, K. Synthesis of sevoflurane loaded reduced graphene oxide nanoparticles system for neuroprotective effects for preconditioning against focal cerebral ischaemia. Artif. Cells Nanomed. Biotechnol. 47, 3517–3523 (2019).
pubmed: 31452399
doi: 10.1080/21691401.2019.1624557
Sairanen, T., Karjalainen-Lindsberg, M. L., Paetau, A., Ijäs, P. & Lindsberg, P. J. Apoptosis dominant in the periinfarct area of human ischaemic stroke—a possible target of antiapoptotic treatments. Brain 129, 189–199 (2006).
pubmed: 16272167
doi: 10.1093/brain/awh645
Shi, C. X. et al. Effects of sevoflurane post-conditioning in cerebral ischemia-reperfusion injury via TLR4/NF-κB pathway in rats. Eur. Rev. Med. Pharmacol. Sci. 22, 1770–1775 (2018).
pubmed: 29630125
Rankovic, M. & Zweckstetter, M. Upregulated levels and pathological aggregation of abnormally phosphorylated Tau-protein in children with neurodevelopmental disorders. Neurosci. Biobehav. Rev. 98, 1–9 (2019).
pubmed: 30550860
doi: 10.1016/j.neubiorev.2018.12.014
Baek, S. et al. Generation of integration-free induced neurons using graphene oxide-polyethylenimine. Small 13, 1–10 (2017).
doi: 10.1002/smll.201601993
Kim, D. et al. Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease. Nat. Nanotechnol. 13, 812–818 (2018).
pubmed: 29988049
pmcid: 6351226
doi: 10.1038/s41565-018-0179-y
Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, 1–23 (2012).
doi: 10.1101/cshperspect.a009399
Liu, Y. et al. Graphene quantum dots for the inhibition of β amyloid aggregation. Nanoscale 7, 19060–19065 (2015).
pubmed: 26515666
doi: 10.1039/C5NR06282A
Murphy, M. P. & Levine, H. Alzheimer’s disease and the amyloid-β peptide. J. Alzheimer’s Dis. 19, 311–323 (2010).
doi: 10.3233/JAD-2010-1221
Liu, C. & Luo, X. Potential molecular and graphene oxide chelators to dissolve amyloid-β plaques in Alzheimer’s disease: a density functional theory study. J. Mater. Chem. B 9, 2736 (2021).
pubmed: 33688880
doi: 10.1039/D0TB02985H
Wang, K. et al. Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer’s disease. Drug Deliv. 28, 580–593 (2021).
pubmed: 33729067
pmcid: 7971267
doi: 10.1080/10717544.2021.1895909